Evidence map›Paper›PMID 32515658›Full record

ArticleGut microbes2020

The protective effect of

Tsutomu Yoshihara, Yosuke Oikawa, Takayuki Kato, Takaomi Kessoku, Takashi Kobayashi, Shingo Kato, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Hidenori Ohkubo and 7 more

Open access · goldAbstract read
In one paragraph

Article in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Peptidoglycan fromBioscience of microbiota, food and health · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Big lessons from the littleFrontiers in immunology · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Microbiome research reports · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Tsutomu YoshiharaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.ORCID 0000-0001-5150-7942
Yosuke OikawaR&D Center, Biofermin Pharmaceutical Co., Ltd ., Kobe, Japan.
Takayuki KatoDepartment of Gastroenterology, International University of Health and Welfare Atami Hospital , Atami, Japan.ORCID 0000-0001-8839-9594
Takaomi KessokuDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Takashi KobayashiDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Shingo KatoDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Noboru MisawaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Keiichi AshikariDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.ORCID 0000-0001-8379-4704
Akiko FuyukiDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Hidenori OhkuboDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Takuma HigurashiDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Yoko TateishiDepartment of Pathology, Yokohama City University Hospital , Yokohama, Japan.
Yoshiki TanakaR&D Center, Biofermin Pharmaceutical Co., Ltd ., Kobe, Japan.
Shunji NakajimaR&D Center, Biofermin Pharmaceutical Co., Ltd ., Kobe, Japan.
Hiroshi OhnoR&D Center, Biofermin Pharmaceutical Co., Ltd ., Kobe, Japan.
Koichiro WadaDepartment of Pharmacology, Faculty of Medicine, Shimane University , Izumo, Japan.ORCID 0000-0001-9231-0556
Atsushi NakajimaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine , Yokohama, Japan.
Yokohama City University · JPInternational University Of Health And Welfare Atami Hospital · JPShimane University · JPYokohama City University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton pump inhibitors (PPIs) can alleviate upper gastrointestinal injury but paradoxically exacerbate aspirin (ASA)-induced small intestine injury. In this study, our goal was to simulate this exacerbation by developing an appropriate animal model, which may help in establishing treatments.

Indexed as

Bifidobacterium bifidumProbioticsAkkermansiaAnimalsAspirinCytokinesDietary SugarsGoblet CellsHumansIntestinal MucosaIntestine, SmallJejunumMaleMiceMice, Inbred C57BLMucusAspirinCytokinesDietary SugarsOmeprazoleProton Pump InhibitorsAkkermansia muciniphilaaspirinBifidobacterium bifidum G9-1intestinal injuryProton pump inhibitor

Identifiers

PMID32515658
PMCPMC7527075
OpenAlexW3033246556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.